Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

373 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Socinski MA, et al. Among authors: thomas ca. N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4. N Engl J Med. 2018. PMID: 29863955 Free article. Clinical Trial.
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Lee A, Coleman S, Deng Y, Kowanetz M, Shankar G, Lin W, Socinski MA; IMpower150 Study Group. Reck M, et al. Among authors: thomas ca. Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25. Lancet Respir Med. 2019. PMID: 30922878 Clinical Trial.
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.
Socinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kong S, Lee A, Coleman S, Zou W, McCleland M, Shankar G, Reck M. Socinski MA, et al. Among authors: thomas ca. J Thorac Oncol. 2021 Nov;16(11):1909-1924. doi: 10.1016/j.jtho.2021.07.009. Epub 2021 Jul 24. J Thorac Oncol. 2021. PMID: 34311108 Free article.
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
Nogami N, Barlesi F, Socinski MA, Reck M, Thomas CA, Cappuzzo F, Mok TSK, Finley G, Aerts JG, Orlandi F, Moro-Sibilot D, Jotte RM, Stroyakovskiy D, Villaruz LC, Rodríguez-Abreu D, Wan-Teck Lim D, Merritt D, Coleman S, Lee A, Shankar G, Yu W, Bara I, Nishio M. Nogami N, et al. Among authors: thomas ca. J Thorac Oncol. 2022 Feb;17(2):309-323. doi: 10.1016/j.jtho.2021.09.014. Epub 2021 Oct 7. J Thorac Oncol. 2022. PMID: 34626838 Free article. Clinical Trial.
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked.
Bodor JN, Patel JD, Wakelee HA, Levy BP, Borghaei H, Pellini B, Costello MR, Dowell JE, Finley G, Huang CH, Neal JW, Nieva JJ, Puri S, Socinski MA, Thomas C, Ross EA, Litwin S, Clapper ML, Treat J. Bodor JN, et al. Clin Lung Cancer. 2023 Nov;24(7):e242-e246. doi: 10.1016/j.cllc.2023.05.003. Epub 2023 May 11. Clin Lung Cancer. 2023. PMID: 37451930 Clinical Trial.
Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial.
Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Miksad R, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin BM, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Ganser C, Wilkinson B, Mackintosh C, Zheng H, Hollis BW, Meyerhardt JA, Fuchs CS. Ng K, et al. Among authors: thomas ca. JAMA. 2019 Apr 9;321(14):1370-1379. doi: 10.1001/jama.2019.2402. JAMA. 2019. PMID: 30964527 Free PMC article. Clinical Trial.
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Powles T, et al. Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051178 Clinical Trial.
Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial.
Brown JC, Rosenthal MH, Ma C, Zhang S, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin B, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Zheng H, Hollis BW, Fuchs CS, Ng K, Meyerhardt JA. Brown JC, et al. Among authors: thomas ca. Cancers (Basel). 2020 Nov 20;12(11):3451. doi: 10.3390/cancers12113451. Cancers (Basel). 2020. PMID: 33233566 Free PMC article.
The impact of low-mode symmetry on inertial fusion energy output in the burning plasma state.
Ralph JE, Ross JS, Zylstra AB, Kritcher AL, Robey HF, Young CV, Hurricane OA, Pak A, Callahan DA, Baker KL, Casey DT, Döppner T, Divol L, Hohenberger M, Pape SL, Patel PK, Tommasini R, Ali SJ, Amendt PA, Atherton LJ, Bachmann B, Bailey D, Benedetti LR, Berzak Hopkins L, Betti R, Bhandarkar SD, Biener J, Bionta RM, Birge NW, Bond EJ, Bradley DK, Braun T, Briggs TM, Bruhn MW, Celliers PM, Chang B, Chapman T, Chen H, Choate C, Christopherson AR, Clark DS, Crippen JW, Dewald EL, Dittrich TR, Edwards MJ, Farmer WA, Field JE, Fittinghoff D, Frenje J, Gaffney J, Gatu Johnson M, Glenzer SH, Grim GP, Haan S, Hahn KD, Hall GN, Hammel BA, Harte J, Hartouni E, Heebner JE, Hernandez VJ, Herrmann HW, Herrmann MC, Hinkel DE, Ho DD, Holder JP, Hsing WW, Huang H, Humbird KD, Izumi N, Jarrott LC, Jeet J, Jones O, Kerbel GD, Kerr SM, Khan SF, Kilkenny J, Kim Y, Geppert-Kleinrath H, Geppert-Kleinrath V, Kong C, Koning JM, Kroll JJ, Kruse MKG, Kustowski B, Landen OL, Langer S, Larson D, Lemos NC, Lindl JD, Ma T, MacDonald MJ, MacGowan BJ, Mackinnon AJ, MacLaren SA, MacPhee AG, Marinak MM, Mariscal DA, Marley EV, Masse L, Meaney KD, Meezan NB, Michel PA, Millot M, Milovich JL, Moody JD, Moore AS, Morto… See abstract for full author list ➔ Ralph JE, et al. Among authors: thomas ca. Nat Commun. 2024 Apr 6;15(1):2975. doi: 10.1038/s41467-024-47302-8. Nat Commun. 2024. PMID: 38582938 Free PMC article.
Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI).
Anderson EC, DiPalazzo J, Lucas FL, Hall MJ, Antov A, Helbig P, Bourne J, Graham L, Gaitor L, Lu-Emerson C, Bradford LS, Inhorn R, Sinclair SJ, Brooks PL, Thomas CA, Rasmussen K, Han PKJ, Liu ET, Rueter J. Anderson EC, et al. Among authors: thomas ca. NPJ Precis Oncol. 2024 Mar 9;8(1):67. doi: 10.1038/s41698-024-00547-4. NPJ Precis Oncol. 2024. PMID: 38461318 Free PMC article.
373 results